BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. - Wikidata - awgldk - TriplyDB

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

http://www.wikidata.org/entity/Q34162272

about

Better therapeutic trials in ovarian cancer.KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.Whole exome sequence analysis of serous borderline tumors of the ovary.KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas Microenvironment and pathogenesis of epithelial ovarian cancer Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.Molecular approaches to personalizing management of ovarian cancer.BRAF gene: From human cancers to developmental syndromes.Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival.Minireview: animal models and mechanisms of ovarian cancer development.Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.Low-grade serous carcinomas of the ovary contain very few point mutations Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.The molecular pathology of ovarian serous borderline tumors.A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.The status of epidermal growth factor receptor in borderline ovarian tumours.Origin of ovarian cancer: molecular profiling Genetic and molecular changes in ovarian cancer.New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.Clinical implications of using molecular diagnostics for ovarian cancers.Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.BRAF mutation testing in clinical practice.Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.Targeted agents and combinations in ovarian cancer: where are we now?The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.Mutation of NRAS is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma.CD73s protection of epithelial integrity: Thinking beyond the barrier.

P2860

Q27691432-81DFA8A6-5FD5-40FB-8D6B-6F56BDFEB5F8 Q33590020-A536B2A5-71DE-46D1-8B2A-441609D83F00 Q33853093-E6D90785-6EE6-4BE3-AF81-41CE21E2280D Q33893010-45CD727D-AD63-4549-9897-049EC04D071D Q34662610-6729BDDB-C77A-401A-9059-51E40579B898 Q34984679-D2A750EF-57DC-4983-94AD-EC3D586EFCF8 Q35041937-B5BA161F-D267-4DA0-852C-75BE3EBCAAD7 Q35060446-951F58BA-11FE-49F8-B79B-96C53430014F Q35419057-7306F272-772C-443F-95E4-A00F5006F216 Q35510378-DBF428E7-E706-45CC-B51A-621C82D0BFA2 Q35760160-EAF60F29-583B-40C3-B6A8-C762187076BF Q35802430-58398305-1D0D-4348-9CFD-8F2DA603670E Q35872729-0CBA5124-5118-4B0E-93B1-313833F33498 Q35872732-3E731B09-98E2-4FC8-A04E-99D1652ADD4C Q35947034-46DE7849-8891-478E-926A-50F418B6E31F Q36346641-9701B3EE-6CCC-4639-A27E-DBA4546E6C31 Q36415602-994B54F3-A5AD-44AA-A2B0-4F81426A9AB3 Q36545843-D4F60B6C-6AA3-470E-B16E-22D8D7AA6A89 Q36604195-899B8775-D150-469B-8B3B-17D5276C4C8A Q36731185-F2DD5D46-5850-46E0-A4CB-4F8176130426 Q36750622-4A80D57B-4C99-4EAF-BD75-81AEB9F5C9B6 Q36768921-10A73945-FED8-40D0-94F7-3A755AE4E946 Q36855249-B44B2502-9764-4E36-83F5-357AB5932963 Q36937081-09E41FF2-0BA0-431B-A001-55D26373F683 Q36963030-E4655E95-4613-46BB-967F-3BA1ADAD797E Q36965228-1280896A-0C0A-4E50-A34E-3EEFE4505C3C Q37094076-8E2830EB-3B49-4AF5-851B-0838741209CC Q37155964-75754C7C-47F8-4D83-BDB4-0FEC42514A5E Q37332490-C22C6DCE-16E9-409A-AE26-32912F673079 Q37382527-A36F80F8-E316-4B20-816A-AC52ADCD3CEF Q37652173-AD5CE6C4-C425-4214-8A50-F22715FE93A0 Q37988572-DB98F7BE-87BA-4729-A168-618FFDAF9079 Q38067436-619F9215-3463-4783-9327-319FECCAACA7 Q38096241-6E67E726-A5FF-45E6-B0D2-40C01DE17504 Q38372474-5A89A8B4-8DE1-4097-B8B4-09CE9D636389 Q38760610-FEC18C9E-C265-46FF-8EB3-CA30BB00A143 Q38787667-A29DBD28-4310-4E08-B29D-0AB1ACB4E38F Q39181808-17D92D63-5EE9-4EF5-B16A-E8D9BC4207EC Q40057309-0A7AAA13-F342-46AC-8A09-6864B20C091C Q40783577-19FBEAFA-27D5-48F2-B7AE-C8F43A627890

P2860

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

http://www.wikidata.org/entity/Q34162272

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@ast

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@en

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@nl

type

label

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@ast

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@en

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@nl

prefLabel

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@ast

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@en

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@nl

P1433

Q34162272-A6D7D538-0FB3-4704-A9E5-6EAF4F8807A9

P1476

Q34162272-21270D4C-357E-4938-B139-C7D62A414BFB

P2093

Q34162272-1ACC04D6-9A13-41C1-87BC-74A90D8F39ED

Q34162272-28104A58-7D5D-40E4-A13E-A9432984C73F

Q34162272-4185AA20-9926-480B-9C8D-665643AD58C4

Q34162272-5C96B0AC-C34A-4D04-96B6-2907718714C9

Q34162272-78A2F5B6-4DC1-435B-8802-166FBAE3F6D9

Q34162272-7AAE9E9E-9929-457A-804E-B016B9FBADF6

Q34162272-7B8898AE-02E4-4666-B3E9-CEC171B1B266

Q34162272-EE1F345F-FE54-46D8-9516-8E5B80055101

Q34162272-FECA81B3-7748-4888-833F-3DBE5998717F

P2860

Q34162272-02F4C76C-4DBE-4D2D-AAB5-449DE7838FB0

Q34162272-14EE6EFD-7C3D-48CC-84A1-63AF319A43A9

Q34162272-22286D4F-2BEF-466D-A9A8-745F50EF6C6D

Q34162272-281584C0-DF97-4AC9-8F53-91D274B9735A

Q34162272-2C550328-38CC-48A6-8E67-9331F48A45E0

Q34162272-30AD1419-168C-4953-92A3-C2C5F981871B

Q34162272-39E98F49-F89B-4BD1-A904-88D85950A1A3

Q34162272-41168898-831C-4E4D-932E-182EBB69DD10

Q34162272-475AE2A0-4C51-4D5A-9CFF-F554D3DB6B9E

Q34162272-4984762D-DBA1-4AC3-AD0D-47303817A419

P304

Q34162272-4BB26447-388A-4D25-8E75-FC0D22C2F209

P31

Q34162272-AA16D0F0-027D-4095-A600-F0C3205303C0

P356

Q34162272-3DCEAF16-60D2-409E-985F-4E35A582A826

P407

Q34162272-E5101B12-C850-4F91-BE7D-22DFB6F92D75

P433

Q34162272-4E21641E-7619-4D25-ADF0-F83E2070C23C

P478

Q34162272-35EBCC31-9656-4B04-A4A4-5619F523BC33

P50

Q34162272-5FB68D2A-D7BA-434B-8086-7B833E74CACA

P577

Q34162272-39284804-6BCF-4435-A92E-58E297565EEF

P5875

Q34162272-10DF1D50-73EA-476B-9404-D2B909DF199F

P698

Q34162272-A26307BE-08E2-4C83-BD85-324262DA34A2

P932

Q34162272-14028D9F-486C-4E6C-86C0-4F8A616EB8F9

P356

AJPATH.2010.100212

P1433

The American Journal of Pathology

P1476

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

@en

P2093

Charlotte Sun

http://www.w3.org/2001/XMLSchema#string

David M Gershenson

http://www.w3.org/2001/XMLSchema#string

Judith K Wolf

http://www.w3.org/2001/XMLSchema#string

Karen H Lu

http://www.w3.org/2001/XMLSchema#string

Kwong-Kwok Wong

http://www.w3.org/2001/XMLSchema#string

Michael T Deavers

http://www.w3.org/2001/XMLSchema#string

Samuel C Mok

http://www.w3.org/2001/XMLSchema#string

Yvonne T M Tsang

http://www.w3.org/2001/XMLSchema#string

Zhifei Zu

http://www.w3.org/2001/XMLSchema#string

P2860

Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays

PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression

Identification of FOXC1 as a TGF-beta1 responsive gene and its involvement in negative regulation of cell growth

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

Oncogenic Braf induces melanocyte senescence and melanoma in mice.

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis.

Diverse tumorigenic pathways in ovarian serous carcinoma.

Origins and molecular pathology of ovarian cancer.

P304

1611-1617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2010.100212

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46036486

http://www.w3.org/2001/XMLSchema#string

P698

20802181

http://www.w3.org/2001/XMLSchema#string

P932

2947258

http://www.w3.org/2001/XMLSchema#string